Avalo Therapeutics (AVTX) Receivables - Other (2016 - 2024)
Avalo Therapeutics (AVTX) has disclosed Receivables - Other for 9 consecutive years, with -$600000.0 as the latest value for Q4 2024.
- For the quarter ending Q4 2024, Receivables - Other fell 541.18% year-over-year to -$600000.0, compared with a TTM value of -$600000.0 through Dec 2024, down 541.18%, and an annual FY2024 reading of -$600000.0, down 541.18% over the prior year.
- Receivables - Other was -$600000.0 for Q4 2024 at Avalo Therapeutics, down from $998000.0 in the prior quarter.
- Across five years, Receivables - Other topped out at $4.3 million in Q3 2020 and bottomed at -$600000.0 in Q4 2024.
- Average Receivables - Other over 5 years is $1.4 million, with a median of $1.4 million recorded in 2022.
- The sharpest move saw Receivables - Other skyrocketed 1958.27% in 2020, then crashed 541.18% in 2024.
- Year by year, Receivables - Other stood at $2.2 million in 2020, then surged by 69.34% to $3.7 million in 2021, then crashed by 48.68% to $1.9 million in 2022, then crashed by 92.91% to $136000.0 in 2023, then plummeted by 541.18% to -$600000.0 in 2024.
- Business Quant data shows Receivables - Other for AVTX at -$600000.0 in Q4 2024, $998000.0 in Q3 2024, and $33000.0 in Q2 2024.